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Conclusion: Bisphosphonate therapy appears to increase bone mineral density and decrease the incidence of
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Abstract   
Background:  Osteogenesis Imperfecta (OI) is a rare, hereditary disorder that involves 
improper collagen synthesis, specifically, that of type 1 collagen, leading to bone 
fragility. There are four types of classification of OI, each varying in severity from 
multiple fractures to perinatal death. Bisphosphonates has recently been recognized as a 
pharmacologic treatment that aids in bone strength. More randomized controlled trials 
have been conducted to examine the efficacy of bisphosphonates in increasing the bone 
mineral density and decreasing the incidence of fractures in children with OI.  
 
Methods:  A comprehensive search of the medical literature was conducted using various 
search modalities including MEDLINE, CINAHL, AND ISI World of Science and using 
the keywords “osteogenesis imperfecta”, “children” and “bisphosphonates”. Specific 
examples of bisphosphonates were also used as keywords in the search such as 
[“pamidronate”OR “alendronate” OR “olendronate” OR risedronate]. Trials were only 
included if published in English after 2003 and if the trial was randomized and 
controlled. Bibliographic reference of prior systematic review was also examined to 
identify applicable literature. Studies were rated using the Jadad criteria.  
 
Results:  Nine articles were found that met the selection criteria, all of which were 
randomized controlled studies. Overall, it was found that in five studies the incidence of 
fractures was decreased in children with OI and in seven studies bone mineral density 
increased in children with OI.  
  
Conclusion:  Bisphosphonate therapy appears to increase bone mineral density and 
decrease the incidence of fractures in children with OI. However, results would be 
strengthened by a larger, longer, randomized controlled study. Many questions about the 
use of bisphosphonates in growing children remain including the long-term effects of 
bisphosphonates, optimal dosing, and more importantly the safety of bisphosphonates in 
children.  
 
Keywords:  Osteogenesis Imperfecta, bisphosphonates, children, pamidronate, 
alendronate, olendronate, risedronate. 
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Efficacy of Bisphosphonates in Increasing Bone Mineral Density and Decreasing the 
Incidence of Fractures in Children with Osteogenesis Imperfecta 
 
BACKGROUND 
 Osteogenesis imperfecta (OI) also known as “brittle bone disease” is a rare, 
hereditary disorder involving improper collagen synthesis, specifically type 1 collagen.1 
This particular type of collagen is found in bone, ligaments, tendons, skin, sclera and 
dentin. Osteogenesis imperfecta is characterized by an array of clinical manifestations 
including osteoporosis with fractures, joint laxity, grey-blue sclera and dentinogenesis 
imperfecta.2 About 80-90% of the patients with OI have mutations in one of the two 
genes that encode for collagen type 1, COL1A1 and COL1A2 which are transmitted as 
autosomal dominant traits.3, 4 Historically, OI has been classified into four clinical types 
by Sillence et al 5(see Table 1), although through recent data by Glorieux et al6, 7 three 
additional types have been included which are not associated with collagen type 1 
mutations.  According to Sillence et al5, type I is the most common autosomal dominant, 
non-deforming characterized by short stature, triangular faces, joint laxity and blue-grey 
sclera and does not have dentinogeneis imperfecta. Type II is perinatally lethal affecting 
babies while in utero or during the following months. Type III is moderately deforming, 
white sclera, short stature, severe scoliosis and dentinogenesis imperfecta. Lastly, type IV 
is similar to type I but with more severe deformity, white sclera and dentinogenesis 
imperfecta.  The additional three types are not associated with blue sclera or 
dentinogenesis imperfecta. Clearly, OI presents in the young and must be treated 
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immediately to prevent serious outcomes associated with this disorder especially, bone 
fragility.  
 Historically, treatment of OI has focused on orthopedic care including, casting, 
splinting and rodding. In addition to orthopedic care, there have been various 
pharmacologic treatments that have not been found to be effective, including anabolic 
steroids, calcium, fluoride, magnesium, arsenic, diluted hydrochloric acid and growth 
hormones.2, 8, 9 It was not until 1987, that Devogelaer et al10 reported the first use of 
bisphosphonates in treatment for children with OI. His study explored the use of 
bisphosphonate in treatment in other bone conditions such as juvenile osteoporosis and 
Paget’s disease of bone.  Bisphosphonates share a similar structure to pyrophosphate, a 
naturally occurring substance known to inhibit bone metabolism. Over time, 
bisphosphonates have evolved beginning with the first generation (e.g. etifronate), to 
second and third generation compounds, such as alendronate, pamidronate, risedronate 
and neridronate. The antiresorptive properties increase approximately ten-fold between 
generations. Newer bisphosphonates, such olpadronate, are even more potent.11 
According to Rogers, bisphosphonates act on osteoclasts, disrupting the pathway and 
inducing death of these cells.12 It is important to note that children with OI have an 
abnormal collagen synthesis, creating bone fragility, thus bone is further reduced by 
osteoclastic activity. In addition, osteoblasts cannot keep up at the rate that osteoclastic 
activity is occurring, thus leading to low bone mineral density (BMD) and increased 
fractures secondary to bone fragility.12 Devogelaer10 in 1987 and Huaux et al13 in 1988, 
were the first to report a decrease in fracture rate and pain, with the use of 
bisphosphonates in children with severe OI. Then in 1997, Bembi et al14 first reported an 
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increase with BMD in children treated with bisphosphonates for period of 22 months to 
29 months. The aims of treatment with bisphosphonates in children with OI are to 
increase bone strength and decrease the number of fractures occurring.  
 The goal of this systematic review is to examine the available medical research 
published to determine the efficacy of various types of bisphosphonates in increasing 
BMD and decreasing the incidence of fractures in children with OI.   
 
METHODS  
 A comprehensive search of the medical literature was conducted using various 
search modalities including MEDLINE, CINAHL and ISI World of Science and using 
the keywords “osteogenesis imperfecta”, “children” and “bisphosphonates”. Specific 
examples of bisphosphonates were also used as keywords in the search such as 
[“pamidronate”OR “alendronate” OR “olendronate” OR “risedronate”]. Inclusion criteria 
for this systematic review were all in English language, randomized controlled trials 
published after 2003 which included children with OI and the use of bisphosphonates for 
decreasing incidence of fractures and increasing BMD. The included studies followed 
children with different types of OI, using various bisphosphonate therapies, mainly for 
looking at the incidence of fractures and increase in BMD.  Excluded were cohort, both 
prospective and retrospective studies and case reports. After inclusion and exclusion 
criteria, nine studies were rated and assessed for quality using the Jadad criteria (see 
Appendix A).  
 After a preliminary search, a 2008 systematic review was located. The author’s 
literature search reviewed seven randomized controlled trials and one prospective cohort 
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study up to April 2007. A bibliography search was done for the seven randomized 
controlled trials that were reviewed in the 2008 systematic review which met all of the 
inclusion and exclusion criteria. An additional two randomized controlled trials, that were 
not included in the 2008 systematic review, met all of the inclusion and exclusion criteria 
and was examined.   
 
RESULTS 
 A total of nine articles which met the inclusion and exclusion criteria were 
examined in this review (See Table 2). The average sample size was approximately 28.3, 
with the largest group studied consisting of 64 children with OI, and the smallest group 
consisting of 10. The shortest study lasted 18 months and the longest study lasted three 
years. All studies included in this review were randomized, controlled studies.  Three 
trials were double-blinded, and in six, neither participants nor observers were blinded. All 
studies looked at children with OI treated with a bisphosphonate either orally or 
intravenously (IV).  
 Each study looked specifically at children with either one type of OI or various 
types of OI. Five studies included children with OI type I, III, and IV, two studies 
specifically included children with OI type I, one study included neonates with just OI 
type III and, lastly, one study included children with OI type III and IV.  Eight trials 
excluded children with OI who had previously received bisphosphonate therapy.   
 Three studies examined intravenous bisphosphonate in children with OI.15-17 
Antoiazzi et al15 examined infants with severe OI type III, 18-44 days old, for 18 months. 
This study design was a prospective, randomized, controlled study. This was not a double 
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blinded study and the method of randomization was not stated. The neonates were 
determined to have OI type III by clinical and radiographic evaluation. The aim of this 
study was to determine the efficacy of bisphosphonate therapy in the neonatal period in 
hopes to determine an appropriate age to start bisphosphonate therapy.  Therapy 
consisted of neridronate 2mg/kg/body weight administered intravenously for two 
consecutive days, at three month intervals. Assigned were three groups: Group A started 
treatment after diagnosis, mean age 37 days, group B started treatment after six months, 
mean age 220 days and group C a historical control group. Vitamin D and calcium were 
maintained through diet or supplementation. Every three months, the number of fractures 
was measured and the fracture incidence was assessed by parental recall and diary 
confirmed by radiography, however, dual energy X-ray absorptiometry (DXA) 
measurements were not obtained due to young children being casted or unable to sit still. 
Results demonstrated a statistically significant decrease in number of fractures (p<0.05) 
in Group A compared to Group B and C during the first six months of treatment. In the 
second six months, groups A and B had a significant decrease in the number of fractures 
(p<0.05) compared to group C.15  
 Gatti et al16 also examined intravenous bisphosphonates in children with OI. This 
study examined prepubertal children with OI types I, III and IV, ages 6-11 for boys and 
ages 6-9 for girls, over three years. The Italian Patients’ Society (IPS) sent children from 
their society affected by OI. The study relied on the original diagnosis by the IPS. This 
study design was a randomized, controlled study. It was not blinded and the method of 
randomization was not stated in the study. The goal of this study was to demonstrate the 
efficacy of IV neridronate in children with OI. Therapy consisted of IV neridronate 2 
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mg/kg/body weight infused for 30 minutes every three months or no treatment, the ratio 
of the treatment group to control group was 2:1. Calcium and vitamin D levels were 
maintained through diet or supplementation. Radiographs at suspected sites of fractures 
were taken at baseline, 12 months and 36 months and DXA measurements were taken 
every six months. Results demonstrated several differences in characteristics between the 
two groups; however, they were not statistically significant. There was a statistically 
significant increase in spine and hip BMD in the treatment group (p<0.001) compared to 
the control group in the first year. During the following two years, there was an increase 
of 10-25% in BMD in the treatment group. During the first year of treatment, 45% of 
patients in the control group and 25% of patient in the treatment group had a non 
vertebral fracture, however this was not found to be statistically significant due to sample 
size. Furthermore, there was a significant decrease in relative risk reduction of fractures 
in the treatment group (RR=0.36; 95% CI, 0.15-0.87; p<0.05) compared to the control 
group, during the first year.16  
  Letocha et al17 studied 18 children with OI type III and IV, ages 4-13, for one 
year with an additional 6-21 months extended treatment period. This study design was a 
randomized, controlled, non-blinded study. The diagnosis of OI in the children was 
reviewed under an Institutional Review Board approved, protocol. Eight children 
included in the study were also co-enrolled in a recombinant growth hormone study. The 
aim of this study was to determine whether IV pamidronate would increase DXA spine 
measurements and improve functional ability. Therapy consisted of IV pamidronate 
10mg/m2/day for three days every three months for one year or placebo. Four children 
included in the treatment group also received 0.06mg/kg/day for six days per week of 
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Humatrope. Children received calcium supplementation. Radiographs and DXA 
measurements were taken at baseline and every six months. After one year, it was 
determined by DXA z-scores that the treatment group had a significant increase in BMD 
compared to the control group, therefore, the treatment group continued for an additional 
6-21 months. Results of this study demonstrated an increase in lumbar DXA z- scores 
(p<0.001) in the treatment group compared to the control group in the first year. 
Additionally, the lumbar DXA z-scores increased (p<0.005) over the second year in the 
treatment group. There was a decrease in the incidence of upper extremity fractures in the 
treatment group (p=0.05) compared to the control group in the first year. However, there 
was not a significant decrease in the incidence of fractures in the lower extremity in the 
treatment group.17  
 There were four studies that examined oral bisphosphonates in children with 
OI.18-21 Bishop et al18 examined 53 children with moderate to severe OI type I, III and IV, 
for a length of two years. This study design was a randomized, double-blinded, dose-
ranging study. The diagnosis of OI was based on phenotype with one or more of the 
following features including recurrent fractures affecting mobility or two or more crush 
fractured vertebrae causing deformity and requiring surgery.  This study examined 
whether children with OI receiving the higher dose of risedronate weekly would have 
fewer fractures than the children with OI receiving the lowest dose of risedronate weekly. 
Therapy consisted of 0.2mg/kg/week, 1mg/kg/week, or 2mg/kg/week of risedronate for 
two years. Calcium supplementation was provided. The number of fractures were 
recorded and reported by families and confirmed by radiographs and DXA measurements 
were taken at each visit. The primary study outcomes measured were fracture incidence 
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and bone measurement outcomes. Results demonstrated that there was an overall 
decrease in the number of fractures during the study compared to two years prior to the 
study (p=.005) in all treatment groups. There was no significant decrease in incidence of 
fractures between the dosing groups. Dual energy x-ray absorptiometry values assessed in 
this study showed an increase in lumbar BMD (p=0.03) and total body BMD (p=0.0006) 
in the group receiving the highest dose of risedronate weekly. Overall, children with OI 
who received the highest dose of risedronate experienced an increase in lumbar and total 
body BMD.18     
  Rauch et al19 examined 26 children and adolescents with OI type I, 4-18 years 
old, for two years. This study design was a prospective, single-center, placebo-controlled, 
double-blinded- study. This study failed to mention method of randomization. The 
diagnosis of OI type I was made clinically. The study examined the safety and efficacy of 
oral risedronate in children with OI type I. Therapy consisted of either 15mg (<40kg) or 
30mg (> 40 kg) once a week or placebo. Children were given calcium and vitamin D for 
supplementation. Radiographs and DXA measurements were obtained at baseline and at 
the end of study. The primary endpoint measured was change in lumbar spine BMD. 
Other endpoints were examined including radiographically confirmed fractures. Results 
of this study demonstrated an increase in lumbar spine BMD (p=0.003) in the treatment 
group when compared to the placebo group. There were no statistically significant 
changes in DXA measurements in hip, total body, radial metaphysic and radial 
diaphysis.19 
 Seikaly et al20 examined 20 children with OI types I, III and IV, 3-15 years old, 
for two years. This study design was a prospective double-blind crossover study.  OI in 
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the children was diagnosed by the Sillence criteria (see Table 1). The aim of this study 
was to determine if daily oral alendronate improves a child’s daily life. Primary endpoints 
included bone density measured by DXA. Secondary endpoints included rate of skeletal 
fractures. Therapy consisted of oral alendronate at a dose 5 or 10mg/d depending on 
weight. Patients who weighed less than 30 kg received 5 mg/d; patients who weighed 
more than 30 kg received 10mg/d. The control group received placebo. Children were 
maintained on alendronate for 12 months before crossing over to placebo for an 
additional 12 months and vice versa. Children received calcium and vitamin D 
supplementation. Dual energy x-ray absorbtiometry and skeletal survery were obtained 
yearly. Results demonstrated a tendency to decrease the frequency of fractures however 
the effect was not statistically significant due to sample size.  There was an increase in 
lumbar BMD (p<0.001) in the treatment group compared to the placebo group. There was 
no significant difference in order of administration of placebo versus alendronate in 
decreasing lumbar BMD (p=0.3623).20  
 Sakkers et al21 examined 34 children with OI types I, III and IV, ages 3-18, for 
two years. Children with OI were selected from a Children’s Hospital database in the 
Netherlands. This study only recruited children with restricted ambulation due to interests 
in functional mobility. The design was a randomized, double blinded, placebo-controlled 
study. The aim of this study was to determine if oral olpadronate has any effects on 
skeletal measurements and functional outcomes in children with OI. Primary endpoints 
were fracture incidence and skeletal densitometries.  Therapy consisted of daily oral 
olpadronate 10mg/m2 or placebo for two years.  Calcium and vitamin D were given as 
supplementation. DXA and skeletal radiographs were obtained at baseline, one year and 
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end of study.  Results of this study demonstrated an increase in spinal BMD (p=0.01) in 
the treatment group compared to the placebo group. Olpadronate was associated with a 
31% reduction in relative risk of fractures long bone fractures (p=0.01) in the treatment 
group compared to the placebo group.21  
 The remaining two studies examined intravenous bisphosphonate compared to an 
oral bisphosphonate in children with OI.22, 23  DiMeglio et al23 studied 18 children with 
OI type I, over the age of three, for two years. This study design was a prospective, 
partially randomized open label study. This study did not include a placebo-control. The 
diagnosis of OI was made by a multidisciplinary team including a geneticist, orthopedic 
surgeon and pediatric endocrinologist. This study examined whether or not there was a 
difference in oral alendronate versus IV pamidronate at increasing BMD. Therapy 
consisted of alendronate 1mg/kg/day orally in the form of tablets over four months and 
pamidronate disodium 1mg/kd/day intravenously for 3 consecutive days every four 
months for two years. Calcium was maintained through diet or supplementation.  Every 4 
months DXA was used to assess spine and total body BMD and radiographs assessed 
fracture history and current fractures annually. Primary endpoints measured were 
increase in BMD. Secondary endpoints, among others, were also examined including 
fracture incidence. Results demonstrated in this partially randomized study, that two 
children were assigned to intravenous therapy for abdominal pain accompanied by heme-
positive stools and difficulty obtaining intravenous access before therapy. Results also 
reported that three children had hardware added and three different children had hardware 
removed during the study. Results of this study demonstrated that children had an 
increase in total body BMD (p<0.01) and lumbar BMD (p<0.01) for both combined oral 
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alendronate and IV pamidronate. There was an overall decrease in the fracture rate in the 
combined group (p<0.05). However, there is no significant difference between treatment 
groups.23   
 DeMeglio et al22 studied 12 children with OI types I, III and IV, ages 3-18, for 
one year. The study design was an open-label, prospective, randomized clinical study. A 
clinical diagnosis of OI was made in the children. The aim of this study was to examine 
the efficacy of oral bisphohosphonates in children with OI compared to IV. Therapy 
consisted of IV pamidronate 1mg/kg/d for three consecutive days every four months or 
daily oral aledronate 1mg/kg for four months. Daily calcium intake was supplemented. At 
every visit, DXA was obtained and fracture history was obtained by parental recall and 
by diary. Suspected fractures were confirmed by radiographs. Primary endpoints were 
changes in BMD. Secondary outcomes, among others, were fracture incidence. Results 
reported that two children broke randomization and were assigned to intravenous group 
because of chronic abdominal pain. Results demonstrated an increase in lumbar and total 
body BMD in both treatment groups (p<0.05). This study also demonstrated a decrease in 
number of fractures in all treatment groups over one year.22      
 
DISCUSSION 
  The characteristics of each study’s population varied slightly.  All studies used 
children primarily 3-18 years old diagnosed with OI, with varying types of OI, except one 
study15 which looked primarily at neonates 18-44 days old with severe OI.15-23 Children 
were excluded in all studies if they had prior bisphosphonate therapy, except one study 
which did not mention whether or not they used that criteria in their selection of 
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children.20 Letocha et al17 included eight children with OI who were also co-enrolled in 
another protocol treatment on recombinant growth hormone; however they found no 
statistically significant difference in those children’s results.17 Five studies16, 18, 20, 21, 23  
included children with OI type I, III, and IV, two studies19, 23 included children with mild 
OI type I and two studies15, 17 included children specifically with severe OI type III and 
IV. Overall, there still seems to be a limited amount of data specifically looking at milder 
forms of OI and other types of OI not associated with collagen type 1 mutations and 
children younger than three. Since, the clinical question is looking at specific outcomes, 
the primary and secondary endpoints examined in this review were specific to fracture 
incidence and BMD.  
 Many of the studies used various bisphosphonates as treatment in children with 
OI.  It seemed that many of the studies included in this review assumed that these drugs 
work efficaciously in the treatment of children with OI and has forged without 
considering the basic questions “does one work better than another”, “what dosage is 
most effective or what route of administration is most effective”.  
 In each study, the route of administration of bisphosphonate differed. Many of the 
studies either looked at an oral or IV administration of a bisphosphonate compared to 
placebo 15-17, 19-21 except one study18  which looked at three different doses to see if one 
particular dose had more of an effect than the other doses. Two studies22, 23 compared an 
IV administered bisphosphonate to an orally administered bisphosphonate. Both oral and 
IV bisphosphonates have demonstrated to be equally safe in children with OI.22, 23 
However, oral administration of bisphosphonates has clear advantages over IV 
administration of bisphosphonates. Clearly, IV administration requires hospitalization 
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which is expensive, time consuming and requires IV access. It also disrupts schooling 
and requires parents to take time off work. However, in children with functional 
immobility, fractures and intolerability with oral medications, IV administration would be 
beneficial option. 
  The dosing of bisphosphonates in each study was comparable when either 
administered orally or intravenously. Bishop et al18 demonstrated that children receiving 
the highest dose of bishphosphonate of 2mg/kg/week experienced an increase in BMD 
compared to the other treatment groups.There remain the questions as to optimal dosing 
of bisphosphonates and duration of treatment of children with OI.   
  Each study looked at many outcomes; however, only the relevant 
outcomes of incidence of fractures and BMD are addressed.  A decrease in incidence of 
fractures was demonstrated in five studies.15-17, 21, 23  Increased bone mineral density was 
reported in seven studies.16-18, 20-23A statistically significant increase in lumbar BMD was 
reported in seven studies16-18, 20-23 , a statistically significant increase in total body BMD 
was reported in three studies18, 22, 23 and a significant increase in hip BMD in one study.16  
Overall, the efficacy of bisphosphonates in decreasing incidence of fractures and 
increasing bone mineral density is a promising.  
 
Limitations 
 There were several limitations for this systematic review. The weakness of the 
studies included in this systematic review was the number of children evaluated in the 
studies. A disorder such as OI is so rare, that a significant result in a study with a 
treatment group of five seems hard to stand a chance of achieving meaningful 
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significance. The largest sample size in this study was 64 participants, thus the results are 
based on a limited study population. The validity of the results of the studies may have 
been easier to validate in a larger population, for example had the studies done a 
multicenter study since OI is rare, the results would have more validity. Many of the 
studies looked at children with various types of OI; however, there is limited data on 
other forms of OI which are not associated with collagen mutations.  
 Another limitation resulted from the fact that many of the studies were not 
blinded. Five studies were not blinded.15-17, 22, 23  By not blinding the participants, 
researches, parents, and clinical staff bias is introduced into the study. This is a limitation 
to the validity of the study. In addition, selection bias was demonstrated in two studies.22, 
23 Participants were randomized to groups but before treatment, were assigned to 
different groups that were randomized to, thus breaking randomization. These two studies 
professed to be randomized but broke randomization. Each study was assigned a Jadad 
score (see Appendix A). Three studies were randomized, controlled, double-blinded 
studies that received a Jadad score of 5.18, 20, 21 Two studies were randomized, controlled 
studies but not blinded, thus receiving a Jadad score of 3.19, 22  Two studies received a 
Jadad score of 2.17, 23  DiMeglio et al was not a blinded study and they verified that they 
broke randomization.23  Letocha et al was not a blinded study and failed to describe 
withdrawals and dropouts.17  Lastly, two studies were not double blinded and method of 
randomization was not mentioned and appropriate, thus they received a Jadad score of 
1.15, 16 
 Four studies relied on parental recall for fracture history prior to treatment and 
during scheduled follow-up appointments that were confirmed by radiographs; however 
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this presents a possible recollection bias.15, 17, 18, 22  Other studies, along with confirming 
any suspected fracture with a radiograph, had orthopedic assessments at baseline and 
follow-up to confirm fracture history that perhaps more reliable than personal 
recollections of parents.  Researchers must place a reliance on data of the past that was 
recorded by parents. Thus, the results of the incidence of fractures must always be 
evaluated with some degree of skepticism.    
 
Confounders 
 Confounding variables are another crucial part of every one of these studies. 
Some populations simply are not equal. As discussed earlier, children with OI have 
varying severities of their disease state.  Two studies reported a significant decrease in 
incidence of fractures in children with severe OI compared another study that looked at 
children with mild OI, and that this difference could be responsible for a detection bias in 
that result in decrease in the incidence of fractures that have been noted in more severe 
types of OI compared to mild types of OI.15, 17 
 DiMeglio et al reported three children had hardware removed and a different three 
children had hardware added which could potentially affect the results of BMD in that 
particular study.23 Once again, the reliance of the BMD results in those studies remains 
skeptical. If the study had dropped those participants and accounted for them in follow-
up, the study might have more internal validity.  
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Further studies  
 Based on the results of the most current research presented here, additional study 
is clearly warranted. Future studies should follow the lead of the literature presented here 
with randomized, controlled, blinded studies, and should improve on their foundation by 
recruiting larger numbers of participants. They should do a better job of confirming the 
diagnosis of OI in their participants, making sure their participants do not have hardware 
implemented in them at the start of their study and making sure all participants are 
supplemented with calcium and vitamin D.    
 It would also be a good idea to consider comparing various bisphosphonates to 
see if one bisphosphonate is more efficacious than the others at improving BMD and 
decreasing incidence of fractures in children with OI. Also, future studies may examine 
the optimal dose of bisphosphonates in treating children with OI.  
 
CONCLUSION 
 Based on the results of this literature review, evidence exists to support that 
bisphosphonates do in fact, decrease the incidence of fractures and increase BMD in 
children with OI. There are adequate amount of studies with internal validity that have 
demonstrated improvement in bone density with bisphosphonates.  Many of the studies 
demonstrated a decrease in the number of fractures; however few studies have 
demonstrated statistically significance due to small sample sizes.  Results would be 
strengthened by a larger, randomized controlled study.  Many questions about the use of 
bisphosphonates in children with OI remain including research to assess the long-term 
effects of bisphosphonates in children with OI, optimal dosing as well as research on the 
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various types of OI not associated with mutations in collagen type 1 and more 
importantly, safety of bisphosphonates in children with OI. 
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TABLES 
 
Table 1: Expanded Sillence Classification of Osteogenesis Imperfecta 
 
Type Clinical Severity Typical features  Typically 
Associated 
Mutations 
    
I Mild non-deforming Normal height or mild stature; blue sclera; no 
dentinogenesis imperfecta 
Premature stop 
codon in COL1A1 
II Prenatal lethal Multiple rib and long-bone fractures at birth; 
pronounced deformities; broad long bones; low 
density of skull bones on radiographs; dark 
scleaa 
Glycine 
substitution in 
COL1A1 or 
COL1A2 
III  Severely deforming Very short; triangular face; severe scoliosis; 
grayish sclera; dentinogenesis imperfecta 
Glycine 
substitutions in 
COL1A1 or 
COL1A2 
IV Moderately 
deforming 
Moderately short; mild to moderate scoliosis; 
grayish or white sclera; denitnogenesis 
imperfecta 
Glycine 
substitutions in 
COL1A1 or 
COL1A2  
V Moderately 
deforming 
Mild to moderate short stature; dislocation of 
radial head; mineralized interosseous membrane; 
hyperplastic callus; white sclera; no 
dentinogenesis imperfecta 
Unknown 
VI Moderately to 
severely deforming 
Moderately short; scoliosis; accumulation of 
osteoid in bone tissue; fish scale pattern of bone 
of lamellation; white sclera; no dentinogenesis 
imperfecta 
Unknown 
 
 
VII Moderately 
deforming 
Mild short stature; short humeri and femora; 
coxa vara; white sclera; no denitogenesis 
imperfecta 
Unknown 
Source: 1
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Table 2: Summary of Reviewed Literature 
Study Patients/ Population Intervention/ length of study Outcome(s) Jadad Score/ Comments 
Bishop et al.  
(2010) 
 
53 children, OI types I, III, 
and IV 
 
0.2, 1, 2mg/kg/week of oral 
risedronate for 2 yrs. 
Increase in lumbar and total body 
BMD with highest dose  
(2mg/kg/week); decrease in # of 
fractures in all treatment groups 
5/5- No placebo, compared 
different doses of 
bisphosphonates. 
Rauch et al.  
(2009) 
 
26 children, OI type I Daily oral risedronate 5 mg 
(<40kg), 10mg (>40kg) or placebo 
for 2 yrs. 
Increase in lumbar BMD   3/5- Not a double blinded 
study. 
DiMeglio, et al. 
(2006) 
 
18 children, OI type I Oral alendronate 1mg/kg/d for 4 
mo.or  IV pamidronate 1mg/kg/d 
for 3  consecutive days q 4 mo. for 
2 yrs. 
Increase in lumbar and total body 
BMD in treatment group; overall 
decrease in fracture rate in 
combined groups  
2/5- Not a double blinded 
study, partially randomized- 2 
children assigned to 
intravenous group 
Antoniazzi et al. 
(2006) 
 
10 neonates , OI type III IV neridronate 2mg/kg for 2 days 
q 3 mo. or placebo for 18 mo. 
Fracture incidence  decreased 
when treatment was started 
immediately after diagnosis  
1/5-Not a double blinded 
study, no method of 
randomization stated 
DiMeglio et al. 
(2005) 
 
12 children, OI with types 
I, III, and IV 
IV pamidronate 1mg/kg/day 3 
consecutive days q 4 months; 
Daily oral aledronate 1 mg/kg for 
1 yr. 
Increase in lumbar and total body 
BMD; demonstrated a decrease in 
fractures- not significant 
3/5- Not a double blinded 
study 
Seikaly et al.  
(2005) 
 
20 children with types I, 
III, IV OI  
Daily oral alendronate 5mg 
(<30kg) or 10mg (>43kg) or 
placebo for 2 yrs 
Increase in lumbar BMD 5/5- Crossover study, double 
blinded study.  
Gatti et al.  
(2005) 
 
64 prepubertal children , 
OI type 
IV Neridronate 2mg/kg infused for 
30 min. q 3 mo or placebo for 3 
yrs 
Increase in lumbar and hip BMD;  
significant decrease in the number 
of fractures  
1/5- Not a double-blinded 
study, no method for 
randomization stated 
Letocha et al.  
(2005) 
 
18 children, OI types III 
and IV 
IV pamidronate 10mg/m2/day for 3 
consecutive days q 3 mo. or 
placebo and 8 children on rGH 
received 0.06mg/kg /d for 6 
days/week for 1 yr. and additional 
6-21 mo. for treatment group  
Increase in lumbar BMD, 
significant decrease in upper 
extremity fractures 
2/5- Not a double blinded 
study, 8 children were given 
injection of growth hormone 
during course of the study 
Sakkers et al.  
(2004) 
 
34 children, OI type I Daily oral olpardronate 10mg/m2/d 
or placebo for 2 yrs 
Increase in lumbar BMD, 
significant decrease in long bone 
fractures 
5/5- double blinded trial 
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 APPENDIX 
 
 Appendix A 
 Description of Jadad Score Critera 
 
Jadad Score Calculation   
Item Score 
Was the study described as randomized (this includes words such as randomly, random, and 
randomization)? 
0/1 
Was the method used to generate the sequence of randomization described and appropriate 
(table of random numbers, computer-generated, etc)? 
0/1 
Was the study described as double blind? 0/1 
Was the method of double blinding described and appropriate (identical placebo, active 
placebo, dummy, etc)? 
0/1 
Was there a description of withdrawals and dropouts? 0/1 
Deduct one point if the method used to generate the sequence of randomization was described 
and it was inappropriate (patients were allocated alternately, or according to date of birth, 
hospital number, etc). 
0/-1 
Deduct one point if the study was described as double blind but the method of blinding was 
inappropriate (e.g., comparison of tablet vs. injection with no double dummy). 
0/-1 
 Source: Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical 
 trials: is blinding necessary? Controlled Clinical Trials.  1996:17[1]: 1-12.  
 
